Gene: ZNF569
Official Full Name: zinc finger protein 569provided by HGNC
Gene Summary: Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be active in nucleus. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO23456 | ZNF569 Knockout cell line (HEK293) | Human | ZNF569 | 1:3~1:6 | Negative | Online Inquiry |
KO23457 | ZNF569 Knockout cell line (A549) | Human | ZNF569 | 1:3~1:4 | Negative | Online Inquiry |
ZNF569 Gene Knockout Cell Lines are genetically modified cellular models that specifically lack the expression of the ZNF569 gene, a member of the zinc finger protein family known to play crucial roles in transcription regulation and cellular signaling. The knockout of this gene provides a powerful tool for studying its biological functions and the pathways it influences. By using CRISPR/Cas9 technology, we ensure efficient and precise gene editing, yielding stable cell lines that enable functional assays, phenotypic characterization, and high-throughput screening.
The key mechanism of ZNF569 knockout involves the targeted disruption of the ZNF569 gene locus, which leads to the loss of protein expression. This loss allows researchers to decipher the downstream effects on cellular processes, such as proliferation, differentiation, and apoptosis. Furthermore, ZNF569 gene loss can shed light on its implications in various diseases, including cancer, where aberrant expression of regulatory genes is often observed.
The importance of ZNF569 Gene Knockout Cell Lines extends into both basic research and clinical applications. They serve as a foundational model for exploring gene function, elucidating the molecular mechanisms involved in pathophysiology, and validating potential therapeutic targets. Additionally, their use in drug discovery can accelerate the identification of novel compounds that modulate ZNF569-related pathways, enhancing translational outcomes.
What sets our ZNF569 Gene Knockout Cell Lines apart from alternative models is the guaranteed specificity and reproducibility of results. Unlike traditional knockout methods, our CRISPR/Cas9 technique minimizes off-target effects, resulting in cell lines that more accurately represent the biological context of ZNF569 deficiency. Moreover, the extensive validation we provide ensures that these cell lines are robust for experiments across various conditions and applications.
Researchers and clinicians seeking reliable cell models for the study of gene function and disease mechanisms will find tremendous value in our ZNF569 Gene Knockout Cell Lines. With our commitment to scientific innovation and quality assurance, we empower the research community to advance their work with confidence. Our company's expertise in genetic engineering and commitment to supporting academic and biotechnology initiatives underscore our role as a leader in the field of biological products.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.